Results 281 to 290 of about 307,974 (304)

Orthotopic models of cancer for preclinical drug evaluation

European Journal of Cancer, 2004
openaire   +1 more source

Failed trials for central nervous system disorders do not necessarily invalidate preclinical models and drug targets

Nature Reviews Drug Discovery, 2016
Anton Bespalov, Bruce Altevogt, Dario Doller   +2 more
exaly  

Evolution of strategies to improve preclinical cardiac safety testing

Nature Reviews Drug Discovery, 2016
Gary Gintant, Norman Stockbridge
exaly  

Evaluation of Drug Candidates for Preclinical Development

2009
openaire   +1 more source

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Nature Reviews Drug Discovery, 2017
George Apostol, Mark F Bear, Aurore Curie   +2 more
exaly  

Drug repositioning for Alzheimer's disease

Nature Reviews Drug Discovery, 2012
Anne Corbett, James A Pickett, Alistair Burns   +2 more
exaly  

Significance of neurochemical parameters in the preclinical evaluation of neuroleptic drugs

Pharmacology & Therapeutics, 1979
F, Cattabeni, C L, Galli, A, Groppetti, G, Racagni   +3 more
openaire   +2 more sources

Organs-on-chips at the frontiers of drug discovery

Nature Reviews Drug Discovery, 2015
Dongeun Huh
exaly  

Yawning behavior for preclinical drug evaluation.

Methods and findings in experimental and clinical pharmacology, 1996
openaire   +1 more source

Preclinical development of molecular-targeted agents for cancer

Nature Reviews Clinical Oncology, 2010
Alberto Ocana, Atanasio Pandiella, Lillian L Siu   +2 more
exaly